5 Peptide Stacks That Actually Work: Evidence-Based Protocols

5 Peptide Stacks That Actually Work: Evidence-Based Protocols

Peptide stacks that work target complementary biological pathways simultaneously, producing effects no single compound can match. This guide covers five evidence-based protocols, their mechanisms, dosing windows, and the research behind each, so you can make an informed decision with your clinician.

Disclosure: This post contains affiliate links. If you purchase through our RealPeptides link, we may earn a commission at no extra cost to you.

Why Stack Peptides at All?

Single peptides are useful. Stacks are precise. The logic is straightforward: most physiological targets, whether GH secretion, tissue repair, or mitochondrial efficiency, involve multiple receptor systems operating in parallel. A single peptide hits one node. A well-designed stack hits two or three simultaneously, and the combined signal can exceed the sum of its parts.

The GH axis is the clearest example. CJC-1295 binds GHRH receptors for sustained baseline GH elevation, while GHRP-6 engages ghrelin receptors for pulsatile GH bursts. Together, published human trials show approximately 5-10x greater GH release than either peptide alone, with preserved physiological pulsatility. Teichman et al. 2006 demonstrated this in a randomised, placebo-controlled, double-blind design: sustained, dose-dependent GH and IGF-I increases at 30-60 mcg/kg weekly.

There is also a dose-efficiency argument. Anecdotal reports from experienced users suggest stacking allows a 30-40% reduction in individual peptide dose while maintaining efficacy, though this has not been formally tested in controlled human trials. [Anecdote, not clinical data.] The implication is that stacks may reduce side effect burden per compound, though this requires individual monitoring.

What follows are five stacks graded by evidence quality, with mechanisms, dosing windows, and caveats. All dosing figures come from published research or established preclinical models unless marked otherwise.

Stack 1: CJC-1295 + Ipamorelin (The Growth Hormone Foundation Stack)

Mechanism

CJC-1295 is a long-acting GHRH analogue with an 8-day half-life following Drug Affinity Complex (DAC) binding. It maintains a sustained GH-releasing signal at the pituitary without suppressing the natural GH pulse pattern. Ionescu and Frohman 2006 confirmed that trough and mean GH secretion both increase with preserved pulsatility, which matters because blunted pulsatility is associated with GH-related side effects.

Ipamorelin is a selective GHRP with a clean pharmacological profile: it stimulates GH release via ghrelin receptors without meaningfully elevating cortisol or prolactin, which distinguishes it from GHRP-6 at higher doses. The combination produces complementary receptor engagement, GHRH pathway plus ghrelin pathway, for amplified GH output that neither peptide achieves alone.

Research Basis

The clinical evidence base for CJC-1295 is stronger than for most peptide protocols. Two randomised controlled trials in The Journal of Clinical Endocrinology and Metabolism established safety and pharmacokinetics in healthy adults. Teichman et al. 2006 showed mean IGF-I increases of 28-48% across dose groups (30, 60, 120, and 180 mcg/kg) with no serious adverse events. The ipamorelin component is supported primarily by preclinical data and pharmacokinetic modelling; direct human RCT data for the combined stack remains limited.

Typical Protocol

CJC-1295 with DAC: 1-2 mg subcutaneously once weekly. Ipamorelin: 100-200 mcg subcutaneously, 1-3 times daily, preferably fasted or pre-sleep to align with natural GH rhythms. Common run lengths are 8-16 weeks with a structured break before reassessment.

Potential side effects include water retention, joint stiffness, and transient elevated fasting glucose. These are GH-class effects and generally resolve with dose reduction. Anyone with insulin resistance should track fasting glucose closely.

For a detailed look at CJC-1295 timing and administration, see our guide on CJC-1295 and Ipamorelin combination.

Stack 2: BPC-157 + TB-500 (The Wolverine Recovery Stack)

Mechanism

This is the most popular injury-focused stack in the peptide space, and it earns that status mechanistically. BPC-157 (Body Protection Compound-157) acts locally at injury sites: it upregulates VEGFR2 for angiogenesis, modulates the nitric oxide system, stimulates fibroblast activity, and supports collagen organisation. Vukojevic et al. 2025 reviewed the breadth of BPC-157's tissue repair actions, including angiogenesis, collagen synthesis, and inflammatory cytokine reduction, across muscle, tendon, ligament, and gastrointestinal tissue.

TB-500 (Thymosin Beta-4 fragment) operates systemically. It promotes actin polymerisation and cellular migration, enabling repair cells to reach injured tissue faster and in greater numbers. The two mechanisms are genuinely complementary: BPC-157 builds the repair scaffold locally while TB-500 mobilises the cellular repair force systemically.

Research Basis

Sikiric et al. 2022 demonstrated BPC-157 (10 mcg daily) improved myotendinous junction healing and preserved muscle function without atrophy by day 72 post-surgery in animal models. The preclinical recovery acceleration data is compelling, though direct human RCT evidence remains sparse.

The closest we have to human clinical data comes from a retrospective case series reviewed in Suhail et al. 2025: 14 of 16 patients (87.5%) reported significant pain relief at 6-12 months following BPC-157 or BPC-157 plus TB-500 knee injections. The sample is small and uncontrolled, but the signal is consistent with the preclinical literature.

BPC-157 also upregulates growth hormone receptor expression in tendon fibroblasts, as shown by Chang et al. 2018, potentiating GH-induced proliferation through JAK2 signalling. This creates an interesting interaction with GH-axis stacks: BPC-157 may enhance local GH sensitivity at healing tissue.

Typical Protocol

BPC-157: 250-500 mcg subcutaneously or intramuscularly daily, preferably near the injury site. TB-500: 2-5 mg subcutaneously once weekly. Run lengths of 6-12 weeks are typical for acute injury management, with ongoing lower-dose maintenance protocols for chronic joint issues.

Important caution: both peptides promote angiogenesis. Individuals with a personal or family history of cancer, or known genetic predisposition to tumour growth, should obtain medical clearance before use. This is not a casual add-on; it requires clinician involvement.

For detailed BPC-157 administration guidance, see our full article on BPC-157 dosing and administration.

Research-grade BPC-157 is available from RealPeptides, where purity certificates accompany each product.

Stack 3: BPC-157 + GHK-Cu (The Collagen and Regeneration Stack)

Mechanism

While the Wolverine Stack targets acute injury, this combination addresses the underlying matrix: collagen quality, tissue architecture, and whole-system regeneration. GHK-Cu (copper peptide) is one of the most gene-regulatory peptides identified to date, modulating expression of approximately 4,000 genes, including collagen synthesis genes, DNA repair genes, and anti-inflammatory pathways. Pickart and Margolina 2015 established GHK-Cu's capacity to stimulate collagen I, III, and elastin synthesis at nanomolar concentrations via TGF-beta and integrin pathway upregulation.

Pickart et al. 2018 extended this analysis across tissue types: GHK-Cu stimulates blood vessel outgrowth, increases collagen and glycosaminoglycan synthesis, and improves tissue repair across skin, lung, bone, liver, and stomach in animal models. Its modulation of metalloproteinases (TIMP-1 and TIMP-2) means it supports organised tissue remodelling, not just collagen deposition.

BPC-157 and GHK-Cu operate through distinct but complementary mechanisms. BPC-157 is angiogenic and pro-repair at the cellular signalling level (VEGFR2, NO system, fibroblast activation). GHK-Cu acts more directly at the fibroblast collagen synthesis level and regulates the broader gene expression environment for regeneration. Neither pathway substitutes for the other, which is why the combination is logically sound even without direct stack-specific clinical trials.

Typical Protocol

GHK-Cu: 1-3 mg intramuscularly or subcutaneously, 2-3 times weekly. BPC-157: 250-500 mcg daily as above. This stack is particularly used for skin quality, joint health, and post-surgical recovery where matrix quality matters as much as acute repair speed.

For deeper context on GHK-Cu's collagen mechanisms, see our dedicated post on GHK-Cu collagen synthesis mechanisms.

Stack 4: MOTS-c + NAD+ (The Mitochondrial Performance Stack)

Mechanism

MOTS-c is a mitochondria-derived peptide encoded in the mitochondrial genome. It is not a synthetic peptide in the conventional sense; it is an endogenous regulator of metabolic homeostasis. As reviewed by Kim et al. 2022, MOTS-c activates AMPK signalling, inhibits mTOR, enhances glucose uptake, promotes lipid oxidation, reduces systemic inflammation, and demonstrates reversal of ageing-related physical decline in animal models.

The pairing with NAD+ precursors (typically NMN or NR) targets the upstream substrate availability for mitochondrial function. MOTS-c signals metabolic adaptation; NAD+ precursors provide the raw material for the enzymatic machinery that AMPK and SIRT1 pathways depend on. The combination addresses both signalling and substrate simultaneously.

Research Basis

MOTS-c research is primarily preclinical and mechanistic. The Kim et al. 2022 review covers MOTS-c's role in stress response, metabolic regulation, and ageing-related decline with detail sufficient to establish plausible mechanisms. Human clinical trials for MOTS-c specifically are not yet published in peer-reviewed form, making this a research-grade application.

This is an important caveat: of the five stacks in this article, the MOTS-c combination has the thinnest human evidence base. The mechanistic rationale is sound; the clinical translation is unconfirmed. Anyone considering this stack should treat it as exploratory research protocol, not established therapy.

Typical Protocol

MOTS-c: 5-10 mg subcutaneously, 2-3 times weekly. NAD+ precursor (NMN or NR): 500-1,000 mg orally daily. SS-31 (a mitochondria-targeted antioxidant peptide) is sometimes added to this combination for additional mitochondrial membrane protection, particularly in older individuals with significant oxidative load.

For more on MOTS-c's mitochondrial mechanisms, see our article on MOTS-c and mitochondrial health.

Stack 5: Semax + Selank (The Cognitive and Stress-Resilience Stack)

Mechanism

Semax is a synthetic analogue of ACTH(4-7) that upregulates BDNF (brain-derived neurotrophic factor) and NGF, supporting neuroplasticity, focus, and neuroprotection. Selank is a heptapeptide analogue of tuftsin with anxiolytic properties, working through GABA modulation and immune-neuroendocrine regulation without the sedation or dependency risk of classical anxiolytics.

The combination addresses cognitive output (Semax: BDNF, focus, processing speed) and cognitive noise reduction (Selank: anxiety, stress reactivity, GABAergic balance) simultaneously. For high-performance individuals who find that cognitive load is limited as much by anxiety and stress response as by raw processing capacity, this stack targets both bottlenecks.

Research Basis

Both peptides have Russian clinical research backgrounds, primarily from the Institute of Molecular Genetics in Moscow, that are not easily accessible in peer-reviewed English-language journals. Published data on Selank in particular covers its anxiolytic and immunomodulatory actions in animal models and small human studies. Direct peer-reviewed RCT data for the combination stack in English-language journals is limited.

This is one area where the evidence grade is lower than for the GH axis or recovery stacks. The mechanistic case is coherent; the clinical validation is incomplete. Treat this as a research application requiring individual monitoring.

Typical Protocol

Semax: 100-300 mcg daily, typically intranasal or subcutaneous. Selank: 100-300 mcg daily, intranasal. Both are short-acting and typically dosed in the morning to align with cognitive work demands. The combination does not produce the stimulant side effects of conventional nootropics; most users report a quieter, more focused baseline rather than an energetic peak.

For a detailed breakdown of Semax's neurological mechanisms, see our post on Semax neuroprotection and cognition.

How to Choose the Right Stack for Your Goal

Goal specificity matters more than compound count. The most common mistake in peptide use, anecdotally reported across the research and self-experimentation community, is stacking too many compounds simultaneously and losing the ability to attribute outcomes or side effects to any single peptide. [Anecdote, not clinical data.]

A practical framework:

• Acute injury recovery: BPC-157 + TB-500. Start here; add GHK-Cu after 4 weeks if matrix quality is a limiting factor.
• GH axis and body composition: CJC-1295 + Ipamorelin. Clinically the most validated combination.
• Skin, joint, and systemic regeneration: BPC-157 + GHK-Cu. Longer-term, lower-urgency protocol.
• Metabolic health and longevity: MOTS-c + NAD+ precursor. Exploratory; monitor metabolic markers.
• Cognitive performance under stress: Semax + Selank. Assess after 4 weeks before adjusting dose.

For safety considerations and contraindication screening relevant to all stacks, our article on safety considerations and contraindications covers the key risk factors in detail.

Timing, Cycling, and Practical Administration

Half-life drives timing. CJC-1295 with DAC (8-day half-life) is dosed weekly; Ipamorelin (2-3 hour half-life) is dosed 1-3 times daily. Running these out of phase defeats the synergy rationale.

BPC-157 (short half-life, sub-30 minutes systemic but longer at injury sites due to local concentration) benefits from daily dosing near the target tissue. TB-500 (longer systemic distribution) can run weekly without re-dosing compromise.

Run lengths of 8-12 weeks with a structured break of 4-6 weeks are the standard self-experimentation template. This is not derived from published human trials; it reflects a precautionary principle applied to compounds without long-term human safety data. [Anecdote and precautionary reasoning, not clinical data.]

Injection site hygiene is non-negotiable. All subcutaneous peptide administration requires aseptic technique: new needle per injection, skin cleaned with alcohol swab, reconstituted peptides stored refrigerated, used within manufacturer-recommended windows.

Evidence Grades: Knowing What You Are Working With

Responsible use requires honest evidence grading. Here is where each stack stands:

• CJC-1295 + Ipamorelin: CJC-1295 has two published human RCTs. Ipamorelin component relies on preclinical and pharmacokinetic data. Combined stack: no published human RCT.
• BPC-157 + TB-500: Extensive preclinical evidence; one small human case series (n=16). Combined stack in humans: preliminary only.
• BPC-157 + GHK-Cu: Mechanistically validated in separate preclinical and in vitro studies; no combined stack human trial.
• MOTS-c + NAD+: Preclinical and mechanistic evidence only; no published human RCT for either compound in this application.
• Semax + Selank: Limited accessible peer-reviewed English-language data; Russian clinical literature exists but lacks systematic review.

The honest summary: the GH axis stack (CJC-1295 + Ipamorelin) has the strongest human evidence foundation. The recovery stacks (BPC-157 combinations) have compelling preclinical evidence and a small but consistent human signal. The mitochondrial and cognitive stacks are mechanistically sound but require further human research before evidence-based clinical recommendations can be made.

Bibliography

• Teichman SL et al. (2006). Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295. J Clin Endocrinol Metab.
• Ionescu M, Frohman LA (2006). Pulsatile Secretion of Growth Hormone Persists during Continuous Stimulation by CJC-1295. J Clin Endocrinol Metab.
• Sikiric P et al. (2022). Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines.
• Chang CH et al. (2018). Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Sci Rep.
• Suhail N et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Orthop Rev.
• Pickart L, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int.
• Pickart L et al. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci.
• Kim SJ et al. (2022). Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Aging Cell.
• Vukojevic J et al. (2025). From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Biomolecules.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.